abstract |
The present invention relates to oligomer compounds (oligomers), which target PBK mRNA in a cell, leading to reduced expression of PBK. Reduction of PBK expression is beneficial for the treatment of diseases or disorders associated with overexpression or undesirably high levels of PBK, such as cancer. |